About 1.8 million Americans will get diagnosed with cancer this year. Nasdaq SRNE, Sorrento Therapeutics Inc, is working to help those Americans and their loved ones cope.
Sorrento Therapeutics is a biopharma company that’s focused on creating therapies for patients suffering from:
- Neurodegenerative diseases
- Autoimmune disorders
- Inflammatory conditions
One of their main techniques involve the delivery of receptor T-cell therapy. Another drug delivery technology, Sofusa, helps bring biologics to a person’s lymphatic system.
If any of these therapies sound familiar, then you’ve likely been paying attention to the news surrounding Covid-19. There’s been a lot of speculation about how the novel virus causes our immune systems to go haywire. Reports are showing that some Covid-19 sufferers develop autoimmune disorders after getting sick. It’s also known to cause a rare inflammatory condition in young children and some adults. Many leading experts believe that T-cells could hold the key to fighting off the virus.
Sorrento Therapeutics’ Strategy
With those ideas in mind, it shouldn’t come as a shock that SRNE is helping develop a coronavirus vaccine right now. That’s not all they’re doing, though. Their coronavirus team is currently focused on:
Clearly, SRNE has a lot on its plate right now. If you’re hoping to invest, then you should bear in mind that SRNE’s idealism can only take them so far. There’s massive competition surrounding coronavirus solutions right now. SRNE isn’t a leader when it comes to testing, and they’re also trailing behind on vaccine trials. That’s not to say they won’t be successful, though. This could be a case of ‘slow and steady wins the race.’
If SRNE is successful, then they’ll still face the challenge of delivering the vaccine.
Due to the factors above, SRNE often isn’t listed as one of the best Covid stocks to invest in.
Despite that, this stock might just be the right pick for you. Even if SRNE’s Covid-related goals fall through, their innovative products offer significant value. Cancer remains one of the leading causes of death around the globe, even amidst this worldwide pandemic. If you’re interested in investing in a cancer solution stock, then SRNE is a solid choice.
|Last Quarterly Earnings|
|P/E Ratio (ttm)||N/A|
|Bid||7.08 x 900|
|Ask||7.08 x 800|
|Dividend & Yield||N/A|